Publications
Casey M, Tozzi F, Wang J, Park KM, Bergsland E, Hope T, Kennecke HF, Rose JB, Babicky M, Irani SS, El-Hayek KM, Hilal MA, Asbun HJ, Cleary S, Smeets P, Berrevoet F, Adam M, Rashidian N, Alseidi A, PNET Diagnosis Research Group. Appropriate use of tissue sampling and somatostatin receptor PET imaging in the diagnosis of pancreatic neuroendocrine tumors: results of an International Delphi Consensus. Surgical endoscopy. 2025. PMID: 40316747
Garje R, Riaz IB, Naqvi SAA, Rumble RB, Taplin ME, Kungel TM, Herchenhorn D, Zhang T, Beckermann KE, Vapiwala N, Carducci MA, Celano P, Hotte SJ, Basu A, Borno H, Bryce AH, Wang P, Wulff-Burchfield E, Bodei L, Loblaw A, Hamilton RJ, Emamekhoo H, Hope TA, He H, Murad MH, Liu H, Williams JE, Parikh RA. Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40315400
Chehrazi-Raffle A, Zugman M, Ebrahimi H, Shodiya MO, Maldonado E, Othman T, Jaime-Casas S, Carrillo RB, Li X, Pal SK, Tripathi A, Zhumkhawala A, Hoeg R, Oliai C, Olin RL, Dorff TB, Mei M. Multicenter analysis of high-dose chemotherapy regimens for the treatment of patients with refractory or recurrent germ cell tumors. ESMO open. 2025. PMID: 40315659
Kwek SS, Yang H, Li T, Ilano A, Chow ED, Zhang L, Chang H, Luong D, Lea A, Clark M, Starzinski A, Shi Y, McCarthy E, Porten S, Meng MV, Ye CJ, Fong L, Oh DY. Identification and regulation of circulating tumor TCR-matched cytotoxic CD4+ lymphocytes by KLRG1 in bladder cancer. JCI insight. 2025. PMID: 40299576
Kwek SS, Yang H, Li T, Ilano A, Chow ED, Zhang L, Chang H, Luong D, Lea A, Clark M, Starzinski A, Shi Y, McCarthy E, Porten S, Meng MV, Ye CJ, Fong L, Oh DY. Identification and regulation of circulating tumor TCR-matched cytotoxic CD4+ lymphocytes by KLRG1 in bladder cancer. JCI insight. 2025. PMID: 40299576
Kwek SS, Yang H, Li T, Ilano A, Chow ED, Zhang L, Chang H, Luong D, Lea A, Clark M, Starzinski A, Shi Y, McCarthy E, Porten S, Meng MV, Ye CJ, Fong L, Oh DY. Identification and regulation of circulating tumor TCR-matched cytotoxic CD4+ lymphocytes by KLRG1 in bladder cancer. JCI insight. 2025. PMID: 40299576
Bando H, Takeda Y, Misumi T, Nishikawa T, Wakabayashi M, Yamazaki K, Oki E, Douillard JY, Punt CJA, Koopman M, Van Cutsem E, Bokemeyer C, Venook AP, Lenz HJ, Maehara Y, Andre T, Shi Q, de Gramont A, Yoshino T. Associations between early tumor shrinkage/depth of response and survivals from the ARCAD database. JNCI cancer spectrum. 2025. PMID: 40280867
Shah NJ, Sura S, Shinde R, Shi J, Bupathi M, Vickery D, Perini R, Motzer RJ. Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Renal Cell Carcinoma Post-Immune-Oncology and Vascular Endothelial Growth Factor Receptor Targeted Therapies. Cancers. 2025. PMID: 40361361
Julia T. Arnold, Oluwadamilola Olaku, Anand Dhruva, Gabriel Lopez, Bhaswati Bhattacharya, Manohar Gundeti, Anupama Kizhakkeveettil, Benmei Liu, Frank Ninivaggi, Sophie King, Jeffrey D. White. Abstract 4992: Results of a survey of US Ayurvedic medicine professionals regarding their work with people with cancer. Cancer research. 2025. PMID:
Toner ER, Rucker M, Wang Z, Larrazabal MA, Cai L, Datta D, Lone H, Boukhechba M, Teachman BA, Barnes LE. Wearable Sensor-based Multimodal Physiological Responses of Socially Anxious Individuals in Social Contexts on Zoom. IEEE transactions on affective computing. 2025. PMID: 40927232
Ge-Ah Kim, Sonali A. Deshpande, Li-Chong Wang, Julia Yu, Hamidreza Sepasizangabadi, Ji Zhang, Jason Au, Kathryn Allaire, Junyan He, Maithreyan Srinivasan, David Y. Oh, Lawrence Fong. Abstract 2179: Multiomic co-detection of proteins, mRNA and protein-protein interactions reveal PD1-PDL1 interactions in the tumor microenvironment of bladder cancer patients treated with anti-PD-L1. Cancer research. 2025. PMID:
Hong CW, Yang Y, Remick I, Su P, Itriago-Leon P, Nickel MD, Fautz HP, Majeed W, Bergsland E, Hope TA, Ohliger MA. Flip Angle Optimization for Hepatobiliary Phase MRI at 0.55 T in Patients With Metastatic Neuroendocrine Tumors: A Prospective Study. AJR. American journal of roentgenology. 2025. PMID: 40237428
Trepka KR, Kidder WA, Kyaw TS, Halsey T, Olson CA, Ortega EF, Noecker C, Upadhyay V, Stanfield D, Steiding P, Guthrie BGH, Spanogiannopoulos P, Dumlao D, Turnbaugh JA, Stachler MD, Van Blarigan EL, Venook AP, Atreya CE, Turnbaugh PJ. Expansion of a bacterial operon during cancer treatment ameliorates fluoropyrimidine toxicity. Science translational medicine. 2025. PMID: 40238917
Trepka KR, Kidder WA, Kyaw TS, Halsey T, Olson CA, Ortega EF, Noecker C, Upadhyay V, Stanfield D, Steiding P, Guthrie BGH, Spanogiannopoulos P, Dumlao D, Turnbaugh JA, Stachler MD, Van Blarigan EL, Venook AP, Atreya CE, Turnbaugh PJ. Expansion of a bacterial operon during cancer treatment ameliorates fluoropyrimidine toxicity. Science translational medicine. 2025. PMID: 40238917
Leyte-Vidal AM, Shah NP. How I individualize treatment for chronic-phase CML. Blood. 2025. PMID: 40239150
Trepka KR, Kidder WA, Kyaw TS, Halsey T, Olson CA, Ortega EF, Noecker C, Upadhyay V, Stanfield D, Steiding P, Guthrie BGH, Spanogiannopoulos P, Dumlao D, Turnbaugh JA, Stachler MD, Van Blarigan EL, Venook AP, Atreya CE, Turnbaugh PJ. Expansion of a bacterial operon during cancer treatment ameliorates fluoropyrimidine toxicity. Science translational medicine. 2025. PMID: 40238917
Koshkin VS, Schafer JM, Scherrer E, Boyiddle C, Schwartz NRM, Yu H, Fang Q, Baker AF, Sayedian FH, Chan E. Testing and Interpretation of Human Epidermal Growth Factor Receptor 2 Protein Expression and ERBB2 Gene Amplification in Advanced Urothelial Carcinoma. JCO precision oncology. 2025. PMID: 40239139
Huppert LA, Mahtani R, Fisch S, Dempsey N, Premji S, Raimonde A, Jacob S, Quintal L, Melisko M, Chien J, Sandoval A, Carcas L, Ahluwalia M, Harpalani N, Hoppenworth J, Blaes A, Blum K, Kim MO, Idossa D, Rao R, Giridhar KV, Rugo HS. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC). NPJ breast cancer. 2025. PMID: 40234477
Huppert LA, Mahtani R, Fisch S, Dempsey N, Premji S, Raimonde A, Jacob S, Quintal L, Melisko M, Chien J, Sandoval A, Carcas L, Ahluwalia M, Harpalani N, Hoppenworth J, Blaes A, Blum K, Kim MO, Idossa D, Rao R, Giridhar KV, Rugo HS. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC). NPJ breast cancer. 2025. PMID: 40234477
Bergo HC, Leak LB, Bivona TG. Condensates as a Culprit in RAS Activation and Inhibitor Resistance. Cancer research. 2025. PMID: 40053457